nCounter® CAR-T Characterization Panel

Helping Your Research

The nCounter CAR-T Characterization Panel was created in collaboration with experts in CAR-T therapy to facilitate the development of robust product release assays. Confidently profile CAR-T products for research and manufacturing applications with an automated, and reproducible assay. Ideally suited for new CAR-T development and QC, the CAR-T Characterization Gene Expression Panel can help streamline the CAR-T manufacturing workflow and potentially reduce vein to vein time. This panel can measure eight essential components of CAR-T biology with 780 human genes. 

Empower your knowledge of CAR-T with the most up-to-date biology developed with experts in the field. 

  • Optimize CAR-T method development
  • Create manufacturing acceptance criteria
  • Measure metabolic fitness and persistence
  • Monitor post-infusion exhaustion and toxicity

How It Works

CAR-T Therapy Workflow

Understanding each step of the CAR-T workflow is critical to ensuring quality and efficacy of the final CAR-T product. The nCounter CAR-T Characterization Panel can be used throughout development and manufacturing as a standardized panel of genes for optimizing methods, developing manufacturing acceptance criteria as well as understanding the host influences beyond manufacturing.

In addition to the standard nSolver™ Analysis, genes included in the CAR-T Characterization panel are organized and linked to various advanced analysis modules to allow for efficient exploration of the eight essential aspects of CAR-T biology.

Advanced Analysis Modules Available for CAR-T Characterization

  • Normalization
  • Quality Control
  • Pathway Analysis
  • Cell Profiling
  • Differential Expression
  • Gene Set Analysis
  • Built-in Compatibility for Panel Plus and Protein Analysis

Panel Selection Tool

Find the gene expression panel for your research with easy to use panel pro

Find Your Panel

Product Information

Partnerships
Specifications
Signatures/ Pathways
TCR Diversity Report
The ROSALIND® Platform
Catalog Information
Partnerships

Partnerships
NanoString is excited to be working with Servier (as project leader), Bayer, Janssen, and Takeda as partners with the Innovative Medicines Initiative (IMI) Consortium in the European Union to develop gold standard analytical methods to use throughout development, manufacturing, and delivery of CAR-T cell therapies. The IMI is the largest public-private partnership in the world dedicated to health research.

Specifications
Signatures/ Pathways
TCR Diversity Report

The TCR Diversity report is available for purchase separately from NanoString for use within the ROSALIND® Platform and evaluates the expression of variable regions of the T cell receptor. The variable regions are assessed for overall expression (above or below background) and normalized to a panel standard which allows for more precise quantification of these variable regions. An estimate of TCR Diversity is calculated and shown relative to designated grouping variables.

The TCR score calculates the diversity of T cell receptor beta variable regions within a sample. The score is based on the Shannon Diversity index calculation, a mathematical measure of species diversity within a community. This ecological calculation accounts for the abundance and evenness of the variable regions present within a given sample versus the population of T cell receptors within a given dataset. A given score is relative within a dataset, and a higher TCR score means there is a more diverse population of variable regions or a less clonal population. A lower TCR score means there is less diversity or a more clonal population. True clonality can only be determined by full sequencing of the T cell receptors, but clonality can be estimated by measuring the diversity of TCR beta variable regions.

Download a demo version of the TCR Diversity Report and open the corresponding TCR Diversity Report-Readme file.

The ROSALIND® Platform

ROSALIND is a cloud-based platform that enables scientists to analyze and interpret differential gene expression data without the need for bioinformatics or programming skills.  ROSALIND makes analysis of nCounter data easy, with guided modules for:

  • Normalization
  • Quality Control
  • Individual Pathway Analysis
  • Differential Expression
  • Gene Set Analysis

nCounter customers can access ROSALIND free of charge.

Catalog Information

Related Resources

See All Resouces
Product Bulletin CAR-T Characterization Panel – Product Bulletin
Poster CAR-T EU Congress 2019 Poster – A Step Toward Standardization with the nCounter® CAR-T Characterization Panel
Poster Molecular Characterization for CAR-T Cell Therapy-Poster

Publications

View All Publications

Biological and Clinical Implications of Gene-Expression Profiling in Diffuse Large B-Cell Lymphoma: A Proposal for a Targeted BLYM-777 Consortium Panel as Part of a Multilayered Analytical Approach.

Simple Summary: This review summarizes gene-expression profiling insights into the background and origination of diffuse large B-cell lymphomas (DLBCL). To further unravel the molecular biology of these lymphomas, a consortium panel called BLYM-777 was designed including genes important for subtype classifications, genetic pathways, tumor-microenvironment, immune response and resistance to targeted therapies.

Molecular and Functional Signatures Associated with CAR T Cell Exhaustion and Impaired Clinical Response in Patients with B Cell Malignancies.

Despite the high rates of complete remission following chimeric antigen receptor (CAR) T cell therapy, its full capacity is currently limited by the generation of dysfunctional CAR T cells. Senescent or exhausted CAR T cells possess poor targeting and effector functions, as well as impaired cell proliferation and persistence in vivo.

PSMA-targeting TGFbeta-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial.

Chimeric antigen receptor (CAR) T cells have demonstrated promising efficacy, particularly in hematologic malignancies. One challenge regarding CAR T cells in solid tumors is the immunosuppressive tumor microenvironment (TME), characterized by high levels of multiple inhibitory factors, including transforming growth factor (TGF)-beta.

Request a Quote

Contact our helpful experts and we’ll be in touch soon.